Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease

Christoph J. Blohmke, Rachel E. Victor, Aaron F. Hirschfeld, Isaac M. Elias, David G. Hancock, Cheryl R. Lane, A. George F. Davidson, Pearce G. Wilcox, Kelly D. Smith, Joerg Overhage, Robert Hancock, Stuart E. Turvey

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Novel therapies to target lung inflammation are predicted to improve the lives of people with cystic fibrosis (CF) but specific antiinflammatory targets have not been identified. The goal of this study was to establish whether TLR5 signaling is the key molecular pathway mediating lung inflammation in CF, and to determine whether strategies to inhibit TLR5 can reduce the damaging inflammatory response. The innate immune responses were analyzed in both airway epithelial cells and primary PBMCs from CF patients and matched controls. Additionally, 151 clinical isolates of Pseudomonas aeruginosa from CF patients were assessed for motility and capacity to activate TLR5. Blood and airway cells from CF patients produced significantly more proin-flammatory cytokine than did control cells following exposure to the CF pathogens P. aeruginosa and Burkholderia cepacia complex (p <0.001). Stimulation with pure TLR ligands demonstrated that TLR signaling appears to mediate the excessive cytokine production occurring in CF. Using complementary approaches involving both neutralizing Ab targeting TLR5 and flagellin-deficient bacteria, we established that inhibition of TLR5 abolished the damaging inflammatory response generated by 'CF airway cells following exposure to P. aeruginosa (p <0.01). The potential therapeutic value of TLR5 inhibition was further supported by our demonstration that 75% of clinical isolates of P. aeruginosa retained TLR5 activating capacity during chronic CF lung infection. These studies identify the innate immune receptor TLR5 as a novel antiinflammatory target for reducing damaging lung inflammation in CF.

LanguageEnglish
Pages7764-7773
Number of pages10
JournalJournal of Immunology
Volume180
Issue number11
DOIs
Publication statusPublished - 1 Jan 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Blohmke, C. J., Victor, R. E., Hirschfeld, A. F., Elias, I. M., Hancock, D. G., Lane, C. R., ... Turvey, S. E. (2008). Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. Journal of Immunology, 180(11), 7764-7773. https://doi.org/10.4049/jimmunol.180.11.7764
Blohmke, Christoph J. ; Victor, Rachel E. ; Hirschfeld, Aaron F. ; Elias, Isaac M. ; Hancock, David G. ; Lane, Cheryl R. ; Davidson, A. George F. ; Wilcox, Pearce G. ; Smith, Kelly D. ; Overhage, Joerg ; Hancock, Robert ; Turvey, Stuart E. / Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. In: Journal of Immunology. 2008 ; Vol. 180, No. 11. pp. 7764-7773.
@article{ea3c9b6c6cc444aca034e20a5d7e531a,
title = "Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease",
abstract = "Novel therapies to target lung inflammation are predicted to improve the lives of people with cystic fibrosis (CF) but specific antiinflammatory targets have not been identified. The goal of this study was to establish whether TLR5 signaling is the key molecular pathway mediating lung inflammation in CF, and to determine whether strategies to inhibit TLR5 can reduce the damaging inflammatory response. The innate immune responses were analyzed in both airway epithelial cells and primary PBMCs from CF patients and matched controls. Additionally, 151 clinical isolates of Pseudomonas aeruginosa from CF patients were assessed for motility and capacity to activate TLR5. Blood and airway cells from CF patients produced significantly more proin-flammatory cytokine than did control cells following exposure to the CF pathogens P. aeruginosa and Burkholderia cepacia complex (p <0.001). Stimulation with pure TLR ligands demonstrated that TLR signaling appears to mediate the excessive cytokine production occurring in CF. Using complementary approaches involving both neutralizing Ab targeting TLR5 and flagellin-deficient bacteria, we established that inhibition of TLR5 abolished the damaging inflammatory response generated by 'CF airway cells following exposure to P. aeruginosa (p <0.01). The potential therapeutic value of TLR5 inhibition was further supported by our demonstration that 75{\%} of clinical isolates of P. aeruginosa retained TLR5 activating capacity during chronic CF lung infection. These studies identify the innate immune receptor TLR5 as a novel antiinflammatory target for reducing damaging lung inflammation in CF.",
author = "Blohmke, {Christoph J.} and Victor, {Rachel E.} and Hirschfeld, {Aaron F.} and Elias, {Isaac M.} and Hancock, {David G.} and Lane, {Cheryl R.} and Davidson, {A. George F.} and Wilcox, {Pearce G.} and Smith, {Kelly D.} and Joerg Overhage and Robert Hancock and Turvey, {Stuart E.}",
year = "2008",
month = "1",
day = "1",
doi = "10.4049/jimmunol.180.11.7764",
language = "English",
volume = "180",
pages = "7764--7773",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

Blohmke, CJ, Victor, RE, Hirschfeld, AF, Elias, IM, Hancock, DG, Lane, CR, Davidson, AGF, Wilcox, PG, Smith, KD, Overhage, J, Hancock, R & Turvey, SE 2008, 'Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease', Journal of Immunology, vol. 180, no. 11, pp. 7764-7773. https://doi.org/10.4049/jimmunol.180.11.7764

Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease. / Blohmke, Christoph J.; Victor, Rachel E.; Hirschfeld, Aaron F.; Elias, Isaac M.; Hancock, David G.; Lane, Cheryl R.; Davidson, A. George F.; Wilcox, Pearce G.; Smith, Kelly D.; Overhage, Joerg; Hancock, Robert; Turvey, Stuart E.

In: Journal of Immunology, Vol. 180, No. 11, 01.01.2008, p. 7764-7773.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Innate immunity mediated by TLR5 as a novel antiinflammatory target for cystic fibrosis lung disease

AU - Blohmke, Christoph J.

AU - Victor, Rachel E.

AU - Hirschfeld, Aaron F.

AU - Elias, Isaac M.

AU - Hancock, David G.

AU - Lane, Cheryl R.

AU - Davidson, A. George F.

AU - Wilcox, Pearce G.

AU - Smith, Kelly D.

AU - Overhage, Joerg

AU - Hancock, Robert

AU - Turvey, Stuart E.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Novel therapies to target lung inflammation are predicted to improve the lives of people with cystic fibrosis (CF) but specific antiinflammatory targets have not been identified. The goal of this study was to establish whether TLR5 signaling is the key molecular pathway mediating lung inflammation in CF, and to determine whether strategies to inhibit TLR5 can reduce the damaging inflammatory response. The innate immune responses were analyzed in both airway epithelial cells and primary PBMCs from CF patients and matched controls. Additionally, 151 clinical isolates of Pseudomonas aeruginosa from CF patients were assessed for motility and capacity to activate TLR5. Blood and airway cells from CF patients produced significantly more proin-flammatory cytokine than did control cells following exposure to the CF pathogens P. aeruginosa and Burkholderia cepacia complex (p <0.001). Stimulation with pure TLR ligands demonstrated that TLR signaling appears to mediate the excessive cytokine production occurring in CF. Using complementary approaches involving both neutralizing Ab targeting TLR5 and flagellin-deficient bacteria, we established that inhibition of TLR5 abolished the damaging inflammatory response generated by 'CF airway cells following exposure to P. aeruginosa (p <0.01). The potential therapeutic value of TLR5 inhibition was further supported by our demonstration that 75% of clinical isolates of P. aeruginosa retained TLR5 activating capacity during chronic CF lung infection. These studies identify the innate immune receptor TLR5 as a novel antiinflammatory target for reducing damaging lung inflammation in CF.

AB - Novel therapies to target lung inflammation are predicted to improve the lives of people with cystic fibrosis (CF) but specific antiinflammatory targets have not been identified. The goal of this study was to establish whether TLR5 signaling is the key molecular pathway mediating lung inflammation in CF, and to determine whether strategies to inhibit TLR5 can reduce the damaging inflammatory response. The innate immune responses were analyzed in both airway epithelial cells and primary PBMCs from CF patients and matched controls. Additionally, 151 clinical isolates of Pseudomonas aeruginosa from CF patients were assessed for motility and capacity to activate TLR5. Blood and airway cells from CF patients produced significantly more proin-flammatory cytokine than did control cells following exposure to the CF pathogens P. aeruginosa and Burkholderia cepacia complex (p <0.001). Stimulation with pure TLR ligands demonstrated that TLR signaling appears to mediate the excessive cytokine production occurring in CF. Using complementary approaches involving both neutralizing Ab targeting TLR5 and flagellin-deficient bacteria, we established that inhibition of TLR5 abolished the damaging inflammatory response generated by 'CF airway cells following exposure to P. aeruginosa (p <0.01). The potential therapeutic value of TLR5 inhibition was further supported by our demonstration that 75% of clinical isolates of P. aeruginosa retained TLR5 activating capacity during chronic CF lung infection. These studies identify the innate immune receptor TLR5 as a novel antiinflammatory target for reducing damaging lung inflammation in CF.

UR - http://www.scopus.com/inward/record.url?scp=47249131603&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.180.11.7764

DO - 10.4049/jimmunol.180.11.7764

M3 - Article

VL - 180

SP - 7764

EP - 7773

JO - Journal of Immunology

T2 - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -